A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures

Epilepsy Research

Volumn 30, Issue 1, 1998, Pages 31-40

  Kälviäinen, Reetta ^a   Brodie, Martin J ^b   Duncan, John ^c   Chadwick, David ^d   Edwards, David ^e   Lyby, Karsten ^e  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b WESTERN INFIRMARY   (United Kingdom)

^c Chalfont Centre for Epilepsy   (United Kingdom)

^d WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^e NOVO NORDISK A S   (Denmark)

Author keywords

Add on therapy; Antiepileptic drugs; Partial seizures; Tiagabine

Indexed keywords

PLACEBO; TIAGABINE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOCAL EPILEPSY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; VERTIGO;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; ELECTROENCEPHALOGRAPHY; EPILEPSIES, PARTIAL; EPILEPSY, COMPLEX PARTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; NIPECOTIC ACIDS; PLACEBOS;

EID: 0344878897     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(97)00082-X     Document Type: Article

References (23)

1. Ben-Menachem E. International experience with tiagabine add-on therapy. Epilepsia. 36(Suppl. 6):1995;S14-S21.
2. Braestrup C., Nielsen E.B., Sonnewald U., Knutsen L.J.S., Andersen K.E., Jansen J.A., Frederiksen K., Andersen P.H., Mortensen A., Suzdak P.D. NO-328 binds with high affinity to the brain uptake carrier. J. Neurochem. 54:1990;639-647.
3. Brodie M.J. Tiagabine in the management of epilepsy. Epilepsia. 38:1997;S23-S27.
4. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia. 32(Suppl. 3):1991;15.
5. COSTART, 1989. Coding Symbols for Thesaurus of Adverse Reaction Terms, 3rd ed. Department of Health and Human Services, Food and Drug Administration, Rockville, MD.
6. Crawford P.M., Engelsman M., Brown S.W., Rentmeester T.W., Pedersen B., Clarke C.E., Hoornstra R., Overweg J., Jonsma M., Rademaker M.V., Kasteleijn-Nolst Trenite D.G.A., Meinardi H., Newton E.R., MacDonald A., Hulsman J., Lassen L.C., Edwards D., Snel S., Mengel H.B. Tiagabine: phase II study of efficacy and safety in adjunctive treatment of partial seizures. Epilepsia. 34(Suppl. 2):1993;182.
7. Gustavson L.E., Chu S.-Y. High performance liquid chromatographic procedure for the determination of tiagabine concentrations in human plasma using electrochemical detection. J. Chromatogr. 574:1992;313-318.
8. Gustavson L.E., Mengel H.B. Pharmacokinetics of tiagabine, a γ-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia. 36:1995;605-611.
9. Gustavson, L.E., Cato, A., Boellner, S.W., Cao, G.X., Quian, J.X., Guenther, H.J., Sommerville, K.W., 1997. Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin. Online J. Curr. Clin. Trials 6, February 3, Doc No. 202, Internet .
10. Gustavson, L.E., Sommerville, K.W., Boellner, S.W., Witt, G.F., Guenther, H.J., Granneman, G.R., 1997. Lack of clinically significant pharmacokinetic drug interaction between tiagabine and valproate. Online J. Curr. Clin. Trials 6, February 18, Doc No. 203, Internet .
11. Leppik H.E. Tiagabine: the safety landscape. Epilepsia. 36(Suppl. 6):1995;S10-S13.
12. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 22:1959;719-748.
13. Meldrum B.S. Anatomy, physiology and pathology of epilepsy. Lancet. 336:1990;231-234.
14. Metha C.R., Patel N.R., Gray R. On computing an exact confidence interval for the common odds ratio in several 2×2 contingency tables. Biometrics. 40:1985;819-825.
15. Nielsen E.B., Suzdak P.D., Andersen K.E., Knutsen L.J., Sonnewald U., Braestrup C. Characterisation of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur. J. Pharmacol. 96:1991;257-266.
16. Pledger G.W., Schmidt D. Evaluation of antiepileptic drug efficacy: a review of clinical trial design. Drugs. 48:1994;498-509.
17. Richens A., Chadwick D.W., Duncan J.S., Dam M., Gram L., Mikkelsen M., Morrow J., Mengel H., Shu V., McKelvy J.F., Pierce M.W. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. Epilepsy Res. 21:1995;37-42.
18. Sachdeo R.C., Leroy R., Krauss G., Drake M., Green P.M., Leppik I., Shu V., Ringham G.L., Sommerville K.W. Tiagabine therapy for complex partial seizures. A dose-frequency study. Arch. Neurol. 54:1997;595-601.
19. So E.L., Wolff D., Graves N.M., Leppik I.E., Cascino G.D., Pixton G.C., Gustavson L.E. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. Epilepsy Res. 22:1995;221-226.
20. Suzdak P.D., Jansen J.A. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia. 316:1995;612-626.
21. Uthman, B., Rowan, J., Ahmann, P.A., Leppik, I.E., Schachter, S.C., Sommerville, K.W.S., Shu, V., 1998. Multicenter randomized dose-response trial of tiagabine as adjunctive therapy for patients with complex partial seizures. Arch. Neurol. (in press).
22. van Elteren P.H. On the combination of independent two sample tests of Wilcoxon. Bull. Inst. Int. Stat. 37:1960;351-361.
23. Zelen M. The analysis of several 2×2 contingency tables. Biometrika. 58:1971;129-137.